CN115006374A - Application of vanillyl butyl ether in preparation of product for treating dandruff and tinea corporis - Google Patents
Application of vanillyl butyl ether in preparation of product for treating dandruff and tinea corporis Download PDFInfo
- Publication number
- CN115006374A CN115006374A CN202210820293.2A CN202210820293A CN115006374A CN 115006374 A CN115006374 A CN 115006374A CN 202210820293 A CN202210820293 A CN 202210820293A CN 115006374 A CN115006374 A CN 115006374A
- Authority
- CN
- China
- Prior art keywords
- butyl ether
- vanillyl butyl
- product
- dandruff
- tinea corporis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VLDFMKOUUQYFGF-UHFFFAOYSA-N 4-(butoxymethyl)-2-methoxyphenol Chemical compound CCCCOCC1=CC=C(O)C(OC)=C1 VLDFMKOUUQYFGF-UHFFFAOYSA-N 0.000 title claims abstract description 50
- 229940078465 vanillyl butyl ether Drugs 0.000 title claims abstract description 48
- 208000001840 Dandruff Diseases 0.000 title claims abstract description 28
- 206010005913 Body tinea Diseases 0.000 title claims abstract description 16
- 208000002474 Tinea Diseases 0.000 title claims abstract description 16
- 201000003875 tinea corporis Diseases 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title description 3
- 239000006071 cream Substances 0.000 claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 2
- 239000000341 volatile oil Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 13
- 229960004125 ketoconazole Drugs 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 7
- 229920004934 Dacron® Polymers 0.000 abstract description 6
- 239000005020 polyethylene terephthalate Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 210000002683 foot Anatomy 0.000 abstract description 5
- 206010067197 Tinea manuum Diseases 0.000 abstract description 4
- 201000004647 tinea pedis Diseases 0.000 abstract description 4
- 230000037380 skin damage Effects 0.000 description 14
- 208000003251 Pruritus Diseases 0.000 description 13
- 241000233866 Fungi Species 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 230000007803 itching Effects 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 241000223229 Trichophyton rubrum Species 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229960005040 miconazole nitrate Drugs 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 208000001126 Keratosis Diseases 0.000 description 2
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 210000004247 hand Anatomy 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 210000004215 spore Anatomy 0.000 description 2
- 210000003046 sporozoite Anatomy 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 241000555688 Malassezia furfur Species 0.000 description 1
- 241000243190 Microsporidia Species 0.000 description 1
- 241000893976 Nannizzia gypsea Species 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- -1 siloxane, propylene Chemical group 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 201000009862 superficial mycosis Diseases 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses an application of vanillyl butyl ether in preparing a product for treating dandruff and tinea corporis, belonging to the technical field of medicines; the application of vanillyl butyl ether in preparing a product for treating dandruff and tinea corporis, wherein the mass concentration of the vanillyl butyl ether is 0.1-5%; the hair conditioner and cream prepared from vanillyl butyl ether can effectively relieve dandruff and tinea manus and pedis, the effect is better than that of ketoconazole and dacron, and the effective addition concentration is 0.1-5%.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to application of vanillyl butyl ether in preparation of a product for treating dandruff and tinea corporis.
Background
Dandruff is a product of metabolism of epidermal cells of the human head, is metabolized from basal layer cells to form an anucleated and inanimate horny layer, and dry dead cells are automatically shed in a scaly or flaky shape, which is commonly called dandruff. The root of dandruff production is the disruption of scalp ecological balance, with the excess bran sporozoite being a major cause. Ketoconazole is currently the most widely used anti-bran sporozoite drug for dandruff treatment. But the treatment effect is not good and the disease is easy to recur.
The superficial mycosis of human body is tinea corporis characterized by itching, skin damage, bacterial plaque and the like after the head, hands, feet, thighs and other parts are infected by superficial fungi such as trichophyton rubrum and the like. The most widely used drugs at present are: miconazole nitrate cream (dacron). The miconazole nitrate cream has the characteristics of slow response time, easy relapse and the like in treatment. Therefore, more effective bacteriostat is needed to be found, and the recurrence rate is reduced.
Disclosure of Invention
The invention aims to provide application of vanillyl butyl ether in preparing a product for treating dandruff and tinea corporis, so as to solve the problems in the background technology.
In order to achieve the purpose, the invention provides the following technical scheme:
the application of the vanillyl butyl ether in preparing products for treating dandruff and tinea corporis is that the mass concentration of the vanillyl butyl ether is 0.1-5%.
As a further scheme of the invention: the mass concentration of the vanillyl butyl ether is 0.1-0.5%.
As a further scheme of the invention: the mass concentration of the vanillyl butyl ether is 0.5%.
As a further scheme of the invention: the products include pharmaceuticals and daily chemicals.
As a further scheme of the invention: the medicine is ointment or spray.
As a further scheme of the invention: the daily chemical product is hair conditioner, cream or essential oil.
Vanillyl butyl ether molecular formula C 12 H 18 O 3 And alias: vanillyl butyl ether, 2-methoxy-4- (butoxymethyl) phenol. CAS is 82654-98-6.
Compared with the prior art, the invention has the beneficial effects that:
1. the vanillyl butyl ether has obvious effect of treating dandruff when the concentration is 0.1 percent, and the in vitro bacteriostasis experiment shows that the vanillyl butyl ether has obvious effect of inhibiting bran spore bacteria when the concentration is 0.1 to 5 percent, and the content is more than 5 percent of ketoconazole.
2. The vanillyl butyl ether has obvious effect of treating tinea corporis of hands, feet, thighs and other parts at the concentration of 0.1 percent, and has obvious inhibition effect on trichophyton rubrum at the concentration of 0.1 to 5 percent through in-vitro bacteriostasis experiments, which is more than miconazole nitrate cream (dacron).
3. Human body experiments show that the hair conditioner and the cream prepared from vanillyl butyl ether can effectively relieve dandruff and tinea manus and pedis, and the effect is better than that of ketoconazole and dacron.
Detailed Description
The technical solution of the present patent will be described in further detail with reference to the following embodiments.
Example 1
A hair conditioner containing vanillyl butyl ether adopts a conventional hair conditioner formula: water, cetostearyl alcohol, cyclopentadimethyl siloxane, propylene glycol, stearyl trimethyl ammonium chloride, amodimethicone, hydroxyethyl cellulose, stearyl trimethyl ammonium chloride; emulsifying in hair conditioner to form emulsion, cooling to 50 deg.C, dividing into three groups, adding 0.1%, 0.5% and 5% vanillyl butyl ether, homogenizing, and keeping.
Example 2
A cream containing vanillyl butyl ether adopts a conventional cream formula: water, squalane, propylene glycol, an A165 emulsifier, and an M68 emulsifier; emulsifying in cream to form emulsion, cooling to 50 deg.C, dividing into three groups, respectively adding vanillyl butyl ether 0.1%, 0.5% and 5%, and homogenizing.
Comparative example 1
The existing dacron is used as comparative example 1.
Comparative example 2
The existing 5% ketoconazole was used as comparative example 2.
Experimental example 1
Antibacterial experiments are carried out on dandruff and tinea corporis related fungi:
strain activation: the Malassezia furfur is cultured in Dixon medium, and added with Tween 80, glycerol monooleate and fatty acid, culture broth for Candida albicans, and culture broth for Trichophyton rubrum and Microsporum gypseum in Sabourne agar.
And (3) culturing bacteria: a9 cm-diameter petri dish was charged with 20mL of a molten culture solution containing 5% agar. Selecting colony, dissolving in sterilized normal saline, mixing well, adjusting turbidity of bacterial suspension to 0.5-1.0OD (equivalent to 5 × 10) 6 -10×10 6 CFU/mL. 0.1ml of the bacterial suspension is sucked up and evenly spread on the surface of a culture medium plate for experiments.
Punching with a puncher with diameter of 7mm, carefully removing agar in the hole, and respectively adding 5% ketoconazole cream, 0.1% vanillyl butyl ether cream, 0.5% vanillyl butyl ether cream and 5% vanillyl butyl ether cream to make the ointment level with the edge of the hole and ensure that the ointment is not added to the agar plane outside the hole.
(4) Culturing: culturing Malassezia at 32 deg.C and the rest strains at 28 deg.C for 7 days.
(5) And (4) observing results: observing the inhibition zone around each ointment hole and recording the diameter, and simultaneously making 3 flat plates for each strain.
The results of the inhibition zones (mm) of dacron and vanillyl butyl ether against 3 superficial fungi (n = 9) are as follows:
| superficial fungi | Daktarin | 0.1% vanillyl butyl ether | 0.5% vanillyl butyl ether | 5% vanillyl butyl ether |
| Trichophyton rubrum | 15.3±2.56 | 17.56±1.80 ■ | 19.56±2.21 ■■ | 23.25±3.20 ■■ |
| Microsporidian gypseum | 12.4±2.24 | 13.42±1.41 ■ | 17.28±2.31 ■■ | 19.26±2.15 ■■ |
| Candida albicans | 18.7±3.15 | 20.52±1.35 ■ | 22.27±2.53 ■■ | 25.57±3.54 ■■ |
Remarking: ■ in comparison with the Daktarin group, p<0.05； ■■ In comparison with the Daktarin group, p<0.01。
The results of ketoconazole versus zone of inhibition (mm) of the dandruff-associated fungus with vanillyl butyl ether (n = 9) are as follows:
| 5% Ketoconazole | 0.1% vanillyl butyl ether | 0.5% vanillyl butyl ether | 5% vanillyl butyl ether | |
| Bran spore bacteria | 15.36±3.20 | 17.28±2.50 ■ | 20.17±2.58 ■■ | 25.35±3.16 ■■ |
Remarking: ■ in comparison with the ketoconazole group, p<0.05； ■■ In comparison with the Daktarin group, p<0.01。
Experimental example 2
Human body experiment for treating tinea manuum and tinea pedis: 30 patients with beriberi are averagely divided into a Daktarin treatment group and a vanillylbutyl ether treatment group according to the disease course and the severity of symptoms, so that the disease conditions of the two groups of patients are similar. The diagnosis refers to the diagnosis standard of tinea manuum and tinea pedis in Chinese clinical dermatology: the disease condition is gradually spread when it is applied to the palms or soles, and the rash is mainly manifested as keratosis, dryness and scales; erythema, papules, blisters, pustules; the finger/toe is soaked and whitened.
Rash and itching symptom score: referring to scoring standard in the guidelines (trial) of clinical research on new Chinese medicines, a 4-grade scoring method is adopted. Degree of itching: no (0 point), no itching feeling; light (1 point), occasional pruritus and no medication, and does not influence work, study and life; in the middle (2 minutes), paroxysmal pruritus, mild and severe, affects sleep, work, study and life and needs to be taken; severe (3 points), severe itching, which seriously affects sleep, work, study, and life. Skin damage condition: erythema, blisters, keratosis, chapping, desquamation, etc., with a severity of 3 points, a medium of 2 points, a mild of 1 point, and no 0 point.
Applying Dakening cream and vanillyl butyl ether cream respectively, applying the ointment after washing feet every day for 1 day and 2 times, continuously for 7 days, and observing the indexes of onset time, symptom improvement degree, cure degree and the like. The recurrence rate is observed after one month of double diagnosis.
The treatment effect evaluation standard is as follows:
and (3) healing: the integral reduction index of the skin damage is 100 percent, the skin damage and the pruritus are completely disappeared, and the microscopic examination of the dandruff fungus is negative;
the effect is shown: most of the skin damage and pruritus disappear, the integral reduction index of the skin damage is more than or equal to 70 percent and less than 100 percent, and the microscopic examination of the fungus on the skin damage is negative;
the method has the following advantages: the skin damage and the pruritus are eliminated, the integral reduction index of the skin damage is more than or equal to 30 percent and less than 70 percent, and the microscopic examination result of the skin damage fungus is negative or positive;
and (4) invalidation: compared with the prior treatment, the method has no progress in all aspects or the disease condition is continuously aggravated, the skin damage integral reduction index is less than 30 percent, and the microscopic examination result of the skin damage fungi is positive.
Results of both groups before and after treatment and comparison of treatment effect (n = 15) were as follows:
| symptom scoring before treatment | Symptom scoring after treatment | Mean onset of action | The cure rate | Recurrence rate after 30 days | |
| Daktarin treatment group | 6.52±1.54 | 2.58±1.51 ▲ | 2.5 | 60% | 33% |
| Vanillyl butyl ether | 6.76±1.36 | 0.70±0.26 ▲■ | 1.5 ■ | 90% ■ | 13% ■ |
Remarking: ▲ p is less than 0.01 compared to before treatment; ■ compared with the Daktarin group, p is less than 0.01.
Experimental example 3
Human experiments for treatment of dandruff: 30 patients with moderate or severe dandruff are averagely divided into a ketoconazole treatment group and a vanillylbutyl ether treatment group (15 cases in each group) according to the disease course and the symptom severity, and the disease conditions of the two groups of patients are similar. Respectively adding hair conditioner mixed with 2% ketoconazole lotion and 0.5% vanillyl butyl ether, cleaning hair, taking a proper amount of hair conditioner, smearing the hair conditioner on the hair, massaging for 3-5 minutes to promote full absorption, keeping for 30 minutes, and then washing to be clean. Continuously observing the indexes such as onset time, symptom improvement degree, cure degree and the like for 7 days.
The standard of cure is as follows: the skin lesions or dandruff are completely removed, and the pruritus disappears; the effect is shown: the skin damage or the scurf is reduced by more than 50 percent, and the pruritus is obviously relieved; the method has the following advantages: the skin damage or the dandruff is reduced by 20 to 50 percent, and the pruritus is relieved; and (4) invalidation: the disease condition was unchanged.
Results of both groups before and after treatment and comparison of treatment effect (n = 15) were as follows:
| cure of disease | Show effect | Is effective | Invalidation | Relapse after 30 days | |
| Ketoconazole treatment groups | 2 | 5 | 6 | 2 | 2 |
| Vanillyl butyl ether | 8 ■ | 5 | 2 | 0 | 2 |
Remarking: ■ compared with the ketoconazole group, p is less than 0.01.
It will be evident to those skilled in the art that the invention is not limited to the details of the foregoing illustrative embodiments, and that the present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.
Furthermore, it should be understood that although the present description refers to embodiments, not every embodiment may contain only a single embodiment, and such description is for clarity only, and those skilled in the art should integrate the description, and the embodiments may be combined as appropriate to form other embodiments understood by those skilled in the art.
Claims (6)
1. The application of the vanillyl butyl ether in preparing products for treating dandruff and tinea corporis is characterized in that the mass concentration of the vanillyl butyl ether is 0.1-5%.
2. Use of vanillyl butyl ether in the manufacture of a product for the treatment of dandruff and tinea corporis according to claim 1, wherein the mass concentration of vanillyl butyl ether is 0.1 to 0.5%.
3. Use of vanillyl butyl ether in the manufacture of a product for the treatment of dandruff and tinea corporis according to claim 1, wherein the mass concentration of vanillyl butyl ether is 0.5%.
4. Use of vanillyl butyl ether according to any one of claims 1 to 3 in the manufacture of a product for the treatment of dandruff and tinea corporis, wherein said product comprises pharmaceutical products and daily use chemicals.
5. Use of vanillyl butyl ether in the manufacture of a product for the treatment of dandruff and tinea corporis according to claim 4, wherein the product is a paste or a spray.
6. Use of vanillyl butyl ether according to claim 4 in the manufacture of a product for the treatment of dandruff and tinea corporis, wherein the daily chemical product is a hair conditioner, cream or essential oil.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210820293.2A CN115006374A (en) | 2022-07-13 | 2022-07-13 | Application of vanillyl butyl ether in preparation of product for treating dandruff and tinea corporis |
| PCT/CN2022/142574 WO2024011868A1 (en) | 2022-07-13 | 2022-12-28 | Use of vanillyl butyl ether in preparation of products for treating dandruff and tinea corporis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210820293.2A CN115006374A (en) | 2022-07-13 | 2022-07-13 | Application of vanillyl butyl ether in preparation of product for treating dandruff and tinea corporis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115006374A true CN115006374A (en) | 2022-09-06 |
Family
ID=83080400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210820293.2A Pending CN115006374A (en) | 2022-07-13 | 2022-07-13 | Application of vanillyl butyl ether in preparation of product for treating dandruff and tinea corporis |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN115006374A (en) |
| WO (1) | WO2024011868A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024011868A1 (en) * | 2022-07-13 | 2024-01-18 | 广州文翰生物科技有限公司 | Use of vanillyl butyl ether in preparation of products for treating dandruff and tinea corporis |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030161802A1 (en) * | 2002-02-05 | 2003-08-28 | Flammer Linda J. | Anti-dandruff and anti-itch compositions containing sensate and sensate enhancer-containing compounds |
| CN101189000A (en) * | 2005-02-14 | 2008-05-28 | 纽罗吉斯克斯公司 | Device for delivery of TRPV1 agonists |
| WO2016100466A1 (en) * | 2014-12-18 | 2016-06-23 | Lubrizol Advanced Materials, Inc. | Amphiphilic suspension and stability agent for antidandruff hair care compositions |
| CN106458861A (en) * | 2014-04-23 | 2017-02-22 | 宝洁公司 | Compositions for deposition on biological surfaces |
| CN112312884A (en) * | 2018-06-22 | 2021-02-02 | 宝洁公司 | Dentifrice composition |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107811889A (en) * | 2017-11-06 | 2018-03-20 | 诺斯贝尔化妆品股份有限公司 | It is a kind of white without Dormant oils warm hand with thermal sensation |
| CN109044936A (en) * | 2018-10-26 | 2018-12-21 | 广州市白云区大荣精细化工有限公司 | A kind of hair nursing cream and preparation method thereof |
| CN115006374A (en) * | 2022-07-13 | 2022-09-06 | 广州文翰生物科技有限公司 | Application of vanillyl butyl ether in preparation of product for treating dandruff and tinea corporis |
-
2022
- 2022-07-13 CN CN202210820293.2A patent/CN115006374A/en active Pending
- 2022-12-28 WO PCT/CN2022/142574 patent/WO2024011868A1/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030161802A1 (en) * | 2002-02-05 | 2003-08-28 | Flammer Linda J. | Anti-dandruff and anti-itch compositions containing sensate and sensate enhancer-containing compounds |
| CN101189000A (en) * | 2005-02-14 | 2008-05-28 | 纽罗吉斯克斯公司 | Device for delivery of TRPV1 agonists |
| CN106458861A (en) * | 2014-04-23 | 2017-02-22 | 宝洁公司 | Compositions for deposition on biological surfaces |
| WO2016100466A1 (en) * | 2014-12-18 | 2016-06-23 | Lubrizol Advanced Materials, Inc. | Amphiphilic suspension and stability agent for antidandruff hair care compositions |
| CN112312884A (en) * | 2018-06-22 | 2021-02-02 | 宝洁公司 | Dentifrice composition |
Non-Patent Citations (2)
| Title |
|---|
| 孙丽囡: "敏感性皮肤的评估及TRPV1的基因多态性研究", 中国知网优秀硕士学位论文全文数据库 医药卫生科技辑, no. 02 * |
| 杨妞妞: "TRPV1参与瘙痒形成及蛇床子素止痒机制研究", 中国知网优秀博士学位论文全文数据库 医药卫生科技辑, no. 08 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024011868A1 (en) * | 2022-07-13 | 2024-01-18 | 广州文翰生物科技有限公司 | Use of vanillyl butyl ether in preparation of products for treating dandruff and tinea corporis |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024011868A1 (en) | 2024-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022516983A (en) | Rhodococcus louver products and their pharmaceutical use | |
| CN107519081A (en) | A kind of composition and preparation method that effect is repaired with anti-acne | |
| CN115006374A (en) | Application of vanillyl butyl ether in preparation of product for treating dandruff and tinea corporis | |
| CN107670027A (en) | Treat the composition and method of skin conditions | |
| CN112353877B (en) | Application of valerian total alkaloid extract in preparation of malassezia inhibitor | |
| CN104888058B (en) | A kind of antibacterial, anti-inflammatory external preparation and preparation method thereof | |
| CN107582691A (en) | Compound phellodendron bark liquid paint is gargled gel | |
| CN114099632B (en) | Chinese medicinal fermented product and its application in preparing medicine for treating fungal infection dermatosis | |
| CN101485675A (en) | Adapalene and hydrochloric clindamycin compound gel preparation and preparation method thereof | |
| CN115337233B (en) | Gel mask with mild acne removing effect and preparation method thereof | |
| CN108078868B (en) | Antiallergic composition for skin care products | |
| CN110075022A (en) | A kind of anti-acne essence and preparation method thereof | |
| JP2002097151A (en) | Skin care preparation | |
| HU186767B (en) | Process for producing compositions for treating dermatologicalanomalys | |
| CN106924279B (en) | Application of TTS-12 of caltrops, traditional Chinese medicine gel for inhibiting trichophyton mentagrophytes and preparation method of traditional Chinese medicine gel | |
| CN113827594A (en) | Scalp antibacterial and anti-inflammatory composition based on solid dispersion technology and preparation method thereof | |
| CN107412647B (en) | External preparation for sterilizing, relieving itching and retaining fragrance | |
| MILLER | Colloidal sulphur in dermatology | |
| CN114272240B (en) | Anti-infection compound preparation and application thereof | |
| CN115300576B (en) | Compound traditional Chinese medicine nanogel for treating beriberi and tinea pedis and preparation method thereof | |
| CN114767708B (en) | Stable gynecological antibacterial composition and gynecological care solution | |
| CN103705441B (en) | A kind of Beclomethasone dipropionate emulsifiable paste | |
| CN111297846A (en) | Anti-acne composition containing lipase inhibitor and alcohol compound | |
| CN114209610B (en) | Acne removing formula and acne removing patch with antibacterial and repairing effects and preparation methods thereof | |
| JP7475873B2 (en) | Defensin expression promoter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220906 |